Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Nausea × Cannabidiol × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2 Anxiety Disorders 2 Sturge-Weber Syndrome 1 Solid Tumor 1 Parasomnias 1 Pain 1 Nausea 1 Marijuana Abuse 1 Glioblastoma 1 Colonic Neoplasms 1 Cognitive Dysfunction 1 Chemotherapy-Induced Peripheral Neuropathy 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Hepatocellular 1 Cancer Pain 1 Breast Carcinoma In Situ 1 Arthralgia 1

Interventions

Aprepitant 11 Palonosetron 8 Dexamethasone 7 Ondansetron 5 Olanzapine 5 netupitant 2 Fluorouracil 2 Calcium Dobesilate 2 yangzheng xiaoji 1 rolapitant 1 ramosetron 1 niraparib 1 netupitant, palosentron drug combination 1 nabiximols 1 isatuximab 1 ginger extract 1 fosaprepitant 1 dolasetron 1 casopitant 1 Tropisetron 1 Therapeutics 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 Oxaliplatin 1 Octreotide 1 Midazolam 1 Leucovorin 1 Lactose 1 L 758298 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡